4.04% 0.8224

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN) 最新ニュース

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN) 最新ニュース

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up Following Insider Buying Activity - MarketBeat

It makes sense and dollars to buy Viridian Therapeutics Inc (VRDN) stock - SETE News

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Bank of New York Mellon Corp - MarketBeat

WilmerHale Advises Underwriters in Upsized $258.8 Million Follow-on Public Offering of Viridian Therapeutics - WilmerHale

Brokers Set Expectations for Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN) - MarketBeat

Viridian Therapeutics (NASDAQ:VRDN) Given New $44.00 Price Target at Royal Bank of Canada - MarketBeat

RBC raises Viridian Therapeutics shares price target, maintains Outperform rating - Investing.com UK

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $31.00 - MarketBeat

Viridian Therapeutics (NASDAQ:VRDN) Shares Up 4.8% on Analyst Upgrade - MarketBeat

Trend Tracker for (VRDN) - Stock Traders Daily

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $38.00 at Needham & Company LLC - Defense World

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - BioSpace

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - StockTitan

Viridian Therapeutics Says Selling 10.7 Mln Shares Of Common Stock At $18.75 Per Share - XM

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire

Viridian Therapeutics launches $150 million public offering - Investing.com India

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Nasdaq

Needham & Company LLC Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - MarketBeat

Viridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat

B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study - Investing.com Canada

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Zacks Investment Research

Needham raises Viridian stock price target, maintains Buy rating By Investing.com - Investing.com Canada

Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Clinical Trials Arena

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load? - Simply Wall St

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $56.00 at BTIG Research - Defense World

Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Yahoo Finance

Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter

Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at HC Wainwright - Defense World

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - BioSpace

After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com Canada

Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED - Scrip

Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from HC Wainwright - MarketBeat

Items Tagged with 'veligrotug' - BioWorld Online

Why are Viridian Therapeutics shares on the rise on Tuesday? - Mugglehead

Viridian Therapeutics launches $150 million public offering - Investing.com

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way (NASDAQ:VRDN) - Seeking Alpha

Viridian Thrives on phase III with veligrotug in thyroid eye - BioWorld Online

After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com South Africa

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition - Investor's Business Daily

After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics - Investing.com India

After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com UK

Viridian Therapeutics launches $150 million public offering By Investing.com - Investing.com UK

Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know - Benzinga

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - StockTitan

Viridian stock jumps on data for lead asset (NASDAQ:VRDN) - Seeking Alpha

Viridian Therapeutics stock gains confidence with improved efficacy and safety data - Investing.com

Viridian Therapeutics price target raised to $40 from $33 at Stifel - TipRanks

Viridian Therapeutics stock gains confidence with improved efficacy and safety data - Investing.com UK

BTIG Research Boosts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $56.00 - MarketBeat

Viridian Therapeutics (VRDN) Shares Cross Above 200 DMA - Nasdaq

Biotech Stock Scores Big Win, Squeezes Shorts - Schaeffers Research

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition - MSN

Viridian's drug cuts thyroid eye disease symptoms in late-stage study - Reuters

Viridian Therapeutics’ eye disorder treatment meets main goal in late-stage study - WKZO

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival - Inkl

Financial Snapshot: Analyzing Viridian Therapeutics Inc (VRDN)’s Key Ratio Metrics - The Dwinnex

Viridian Therapeutics Inc (VRDN)’s stock performance: a year in review - US Post News

Why Is Viridian Therapeutics Stock Trading Higher On Tuesday?Viridian Therapeutics (NASDAQ:VRDN) - Benzinga

VRDNViridian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Viridian Therapeutics Shares Rise on Positive Results of Veligrotug in Thyroid Eye Disease Trial - MarketWatch

Viridian Therapeutics rises as eye disorder treatment meets main goal in late-stage study - XM

Viridian Therapeutics’ Veligrotug Triumphs in THRIVE Trial - TipRanks

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - StockTitan

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 - Business Wire

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Candriam S.C.A. - MarketBeat

Viridian Therapeutics Inc (VRDN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Market Momentum: Viridian Therapeutics Inc (VRDN) Registers a -9.23 Decrease, Closing at 13.47 - The Dwinnex

Viridian Therapeutics (NASDAQ:VRDN) Shares Down 6.3% - MarketBeat

VRDNに似た銘柄